SCHEMBL21943516

SCHEMBL21943516

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Oc1cc(-c2cccnc2)nc2[nH]ccc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIKFYVE Q9Y2I7 6/20 0.75
▸ BRAF P15056 7/20 0.56
▸ CSF1R P07333 4/20 0.56
▸ ABL1 P00519 4/20 0.54
▸ BCR P11274 3/20 0.54
▸ TEK Q02763 2/20 0.54
▸ KDR P35968 3/20 0.51
▸ MAPK14 Q16539 4/20 0.49
▸ KIT P10721 2/20 0.49
▸ LCK P06239 3/20 0.48
▸ SRC P12931 3/20 0.48
▸ ESYT2 A0FGR8 2/20 0.48
▸ NBAS A2RRP1 2/20 0.48
▸ CNOT1 A5YKK6 2/20 0.48
▸ TBKBP1 A7MCY6 2/20 0.48
▸ AGPS O00116 2/20 0.48
▸ MYO1F O00160 2/20 0.48
▸ SNAP23 O00161 2/20 0.48
▸ AP3B1 O00203 2/20 0.48
▸ PSMD12 O00232 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21943532 0.94 PIKFYVE (0.68) PIKFYVEBRAFCSF1RABL1BCR
SCHEMBL21943518 0.92 PIKFYVE (0.64) PIKFYVEBRAFCSF1RABL1TEK
SCHEMBL21944047 0.88 PIKFYVE (0.67) PIKFYVEBRAFCSF1RABL1BCR
SCHEMBL21943016 0.87 PIKFYVE (0.70) PIKFYVEBRAFCSF1RABL1BCR
SCHEMBL21943014 0.87 PIKFYVE (0.65) PIKFYVEBRAFCSF1RABL1BCR
SCHEMBL21943533 0.86 KDR (0.58) PIKFYVEBRAFCSF1RABL1TEK
SCHEMBL22024870 0.86 PIKFYVE (1.00) PIKFYVEBRAFCSF1RABL1BCR
SCHEMBL30675086 0.86 PIKFYVE (1.00) PIKFYVEBRAFCSF1RABL1BCR
SCHEMBL21943517 0.85 TEK (0.57) PIKFYVEBRAFCSF1RABL1BCR
SCHEMBL21943007 0.84 PIKFYVE (0.61) PIKFYVEBRAFCSF1RABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof XIAMEN UNIVERSITY (CN) 2022-05-03 — — US disclosed
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP4A11, CYP2D6, CYP3A43 PIKFYVE 2706/4885BRAF 95/4885CSF1R 3749/4885
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof CYP4A11, CYP2D6, CYP3A43 PIKFYVE 2706/4885BRAF 95/4885CSF1R 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback